141286-84-2

Basic information

• Product Name: {4-[2-(1,3-dioxo-1,3-dihydroisoindol-2-yl)ethylsulfanyl]-2,6-difluorophenoxy}acetic acid ethyl ester
• Synonyms: {4-[2-(1,3-dioxo-1,3-dihydroisoindol-2-yl)ethylsulfanyl]-2,6-difluorophenoxy}acetic acid ethyl ester
• CAS NO: 141286-84-2
• Molecular Weight: 421.421
• Mol File: 141286-84-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: {4-[2-(1,3-dioxo-1,3-dihydroisoindol-2-yl)ethylsulfanyl]-2,6-difluorophenoxy}acetic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: {4-[2-(1,3-dioxo-1,3-dihydroisoindol-2-yl)ethylsulfanyl]-2,6-difluorophenoxy}acetic acid ethyl ester(141286-84-2)
• EPA Substance Registry System: {4-[2-(1,3-dioxo-1,3-dihydroisoindol-2-yl)ethylsulfanyl]-2,6-difluorophenoxy}acetic acid ethyl ester(141286-84-2)

Safety Data

• Hazardous Substances Data: 141286-84-2(Hazardous Substances Data)

Upstream product

• 539-74-2 Ethyl 3-bromopropionate 
• 169298-43-5 N-<2-(3,5-difluoro-4-hydroxyphenylthio)ethyl>phthalimide 
• 151389-57-0 3,5-difluoro-4-hydroxybenzenesulfonyl chloride 
• 151389-58-1 2,6-difluoro-4-mercaptophenol 
• 28177-48-2 2,6-difluorophenol 
• 574-98-1 2-(2-bromoethyl)isoindoline-1,3-dione 
• 105-36-2 ethyl bromoacetate 

Relevant articles and documents

PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH AMPA RECEPTORS

This prophylactic and/or therapeutic agent for diseases associated with AMPA receptors contains a compound represented by formula (I), or a pharmaceutically acceptable salt or solvate thereof. (In the formula, A and Z independently represent CO, SO or SO

Synthesis and evaluation of novel fluorinated sulotroban-related sulfonamide derivatives as thromboxane A2 receptor antagonists

A series of sulotroban-related arylsulfonamide derivatives possessing a fluorinated phenoxyacetic acid moiety was synthesized and tested for TXA2 antagonizing ability on U-46619-induced platelet aggregation of rabbit platelet-rich plasma. Introduction of one or more fluorine atoms to the phenoxyacetic acid moiety increased this activity. The most potent compound among these compounds was 10c, which was 40-fold more potent (IC50 3.4 x 10-7 M) than sulotroban. 10c exhibited high activity (ID50 0.14 mg/kg) against a D-46619-induced acute thrombocytopenia model in mice when orally administrated. These findings and those of radioligand binding assays with various ligands showed 10c to be a potent and selective systemic TXA2 receptor antagonist.